- Investing Ideas
- Hong Kong Healthcare Undervalued based on future growth
Hong Kong Healthcare Undervalued based on future growth
Results
7
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
7 companies
Sinopharm Group
Market Cap: HK$49.9b
Engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People’s Republic of China.
1099
HK$15.79
7D
-3.6%
1Y
-15.3%
Beijing Chunlizhengda Medical Instruments
Market Cap: HK$5.4b
Engages in the research, development, production, and sale of surgical implants, instruments, and related products in the People’s Republic of China and internationally.
1858
HK$8.34
7D
-5.3%
1Y
-27.5%
Hygeia Healthcare Holdings
Market Cap: HK$5.4b
Offers oncology healthcare services in the People's Republic of China.
6078
HK$8.72
7D
-0.7%
1Y
-42.5%
LEPU ScienTech Medical Technology (Shanghai)
Market Cap: HK$3.5b
An investment holding company, engages in the manufacture and sale of interventional treatment series occluders and heart valve medical devices.
2291
HK$9.96
7D
14.1%
1Y
-49.5%
Chaoju Eye Care Holdings
Market Cap: HK$1.6b
Owns and operates a network of ophthalmic hospitals and centers in the People’s Republic of China.
2219
HK$2.34
7D
-6.4%
1Y
-16.1%
Sisram Medical
Market Cap: HK$1.1b
Engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home-use devices, injectables, and cosmeceutical products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America.
1696
HK$2.24
7D
-5.9%
1Y
-48.6%
Yonghe Medical Group
Market Cap: HK$1.0b
Provides hair-related healthcare services in China.
2279
HK$2.07
7D
0%
1Y
44.8%